Meshandra Williams
Family · Bradenton, FLNPI 1366923393
Payments from drug & device makers
Across 356 payments — averaging $24.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$2K
- Alkermes, Inc.$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$565
- Teva Pharmaceuticals USA, Inc.$536
- plus $2K from 18 others
What the payments were for
- Food & beverage$8,57899%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 69 | $2,123 |
| Alkermes, Inc. | 44 | $1,183 |
| AbbVie | 64 | $1,120 |
| Otsuka America Pharmaceutical, Inc. | 37 | $1,000 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $565 |
| Teva Pharmaceuticals USA, Inc. | 23 | $536 |
| Neurocrine Biosciences, Inc. | 28 | $499 |
| Johnson & Johnson | 11 | $327 |
| Tempus AI, Inc | 17 | $218 |
| Jazz Pharmaceuticals Inc. | 5 | $181 |
| Axsome Therapeutics, Inc. | 3 | $169 |
| Avanir Pharmaceuticals, Inc. | 3 | $144 |
| Almatica Pharma LLC | 7 | $119 |
| Lundbeck LLC | 5 | $114 |
| Corium, LLC | 6 | $88 |
| Indivior Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 1 | $32 |
| Sunovion Pharmaceuticals Inc. | 1 | $29 |
| Merck | 1 | $25 |
| Neos Therapeutics, LP | 1 | $20 |
| Sage Therapeutics, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,632 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 13 | $97,895 |
| Invega SustennaPaliperidone Palmitate | 30 | $78,999 |
| VraylarCariprazine Hcl | 35 | $49,238 |
| RexultiBrexpiprazole | 24 | $35,595 |
| Risperdal ConstaRisperidone Microspheres | 33 | $18,714 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 86 | $12,148 |
| Olanzapine | 190 | $6,116 |
| Quetiapine Fumarate | 276 | $4,832 |
| Lurasidone Hcl | 36 | $4,059 |
| Bupropion XlBupropion Hcl | 236 | $3,134 |
| Doxepin Hcl | 139 | $2,813 |
| Buprenorphine Hcl | 34 | $2,522 |
| Duloxetine Hcl | 184 | $2,501 |
| Fluphenazine Decanoate | 18 | $2,423 |
| Aripiprazole | 92 | $1,853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $536 | $97,89513 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $327 | $97,71363 claims |
| AbbVieVraylar | $1,120 | $49,23835 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,000 | $35,59524 claims |
| Almatica Pharma LLCSertraline Hcl | $119 | $1,064170 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Bradenton
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.